Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
PharmaShots
Top 20 Cardiometabolic Prescription Drugs of 2026
Shots: 20. Xultophy Non-Proprietary Name: Insulin degludec/liraglutide Company: Novo Nordisk First Approved: EU (2014), US (2016) FY2025 Revenue: $0.72B FY2024 Revenue: $0.62B YoY Growth: +15.7% 19. Kerendia Non-Proprietary Name: Finerenone Company: Bayer First Approved: US (2021), EU (2022) FY2025 Revenue: $0.97B FY2024 Revenue: $0.48B YoY Growth: +102% 18. Leqvio Non-Proprietary Name: Inclisiran Company: Novartis First Approved: US (2021), EU (2020) FY2025 Revenue: $1.19B FY2024 Revenue: $0.75B YoY Growth: +58.9% 17.… The post Top 20 Cardiometabolic Prescription Drugs of 2026 appeared first on PharmaShots.
Read Full Article
Pharma Tech
FDA puts commissioner’s priority voucher framework on ice
Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.
Read Full Article
Express Pharma
From volume to value: How India’s pharma industry can move up the global value chain
Arun Patel, Founder and Partner, Arunasset Investment Services, explains how India’s pharma industry can move beyond volume-led growth and strengthen its position in the global value chain The post From volume to value: How India’s pharma industry can move up the global value chain appeared first on Express Pharma.
Read Full Article
Pharma Tech
Neurosterix pockets $105m to advance neuropsychiatry pipeline
Neurosterix hopes that NTX-253 may compete with BMS’s Cobenfy as the schizophrenia field explores mechanisms past dopamine modulation.
Read Full Article
Express Pharma
NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs
State Drug Controllers asked to monitor revised prices and submit action taken reports by 16 November The post NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs appeared first on Express Pharma.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Nov 13, 2026, 1:30 PM
Top 20 Cardiometabolic Prescription Drugs of 2026
Shots: 20. Xultophy Non-Proprietary Name: Insulin degludec/liraglutide Company: Novo Nordisk First Approved: EU (2014), US (2016) FY2025 Revenue: $0.72B FY2024 Revenue: $0.62B YoY Growth: +15.7% 19. Kerendia Non-Proprietary Name: Finerenone Company: Bayer First Approved: US (2021), EU (2022) FY2025 Revenue: $0.97B FY2024 Revenue: $0.48B YoY Growth: +102% 18. Leqvio Non-Proprietary Name: Inclisiran Company: Novartis First Approved: US (2021), EU (2020) FY2025 Revenue: $1.19B FY2024 Revenue: $0.75B YoY Growth: +58.9% 17.… The post Top 20 Cardiometabolic Prescription Drugs of 2026 appeared first on PharmaShots.
Pharma Tech
Nov 13, 2026, 11:40 AM
FDA puts commissioner’s priority voucher framework on ice
Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.
Express Pharma
Nov 13, 2026, 11:32 AM
From volume to value: How India’s pharma industry can move up the global value chain
Arun Patel, Founder and Partner, Arunasset Investment Services, explains how India’s pharma industry can move beyond volume-led growth and strengthen its position in the global value chain The post From volume to value: How India’s pharma industry can move up the global value chain appeared first on Express Pharma.
Pharma Tech
Nov 13, 2026, 11:28 AM
Neurosterix pockets $105m to advance neuropsychiatry pipeline
Neurosterix hopes that NTX-253 may compete with BMS’s Cobenfy as the schizophrenia field explores mechanisms past dopamine modulation.
Express Pharma
Nov 13, 2026, 11:15 AM
NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs
State Drug Controllers asked to monitor revised prices and submit action taken reports by 16 November The post NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs appeared first on Express Pharma.
PharmaShots
Nov 13, 2026, 11:12 AM
Daiichi Sankyo Submits sNDA to Japan’s MHLW for Enhertu to Treat HER2 Expressing Uterine Carcinosarcoma
Shots: Daiichi Sankyo has submitted an sNDA to Japan’s MHLW for Enhertu (trastuzumab deruxtecan) to treat patients with HER2 expressing (IHC 3+, 2+ or 1+) advanced or recurrent uterine carcinosarcoma The filing is based on the investigator-initiated P-II (STATICE) trial (n=34) conducted at 7 sites in Japan, in which Enhertu (5.4mg/kg) showed durable responses across… The post Daiichi Sankyo Submits sNDA to Japan’s MHLW for Enhertu to Treat HER2 Expressing Uterine Carcinosarcoma appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 13, 2026, 1:54 PM
USFDA's Fast-Track Drug Review Programme Under Trump Administration Falls Into Limbo - Medical Dialogues
USFDA's Fast-Track Drug Review Programme Under Trump Administration Falls Into Limbo Medical Dialogues
Google News
Nov 13, 2026, 1:48 PM
Global 3D Printing Drugs Market to Reach $540.4 Million by 2031 - GlobeNewswire
Global 3D Printing Drugs Market to Reach $540.4 Million by 2031 GlobeNewswire
Google News
Nov 13, 2026, 1:35 PM
Why Israel’s cancer-drug industry should examine Jordan’s nuclear reactor - The Jerusalem Strategic Tribune
Why Israel’s cancer-drug industry should examine Jordan’s nuclear reactor The Jerusalem Strategic Tribune
Google News
Nov 13, 2026, 1:31 PM
Legend Biotech Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
Legend Biotech Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions Simply Wall St
Google News
Nov 13, 2026, 1:00 PM
Opinion: The science of vaccines is rapidly advancing — despite the anti-vax movement - MarketWatch
Opinion: The science of vaccines is rapidly advancing — despite the anti-vax movement MarketWatch
Google News
Nov 13, 2026, 12:44 PM
Centre directs states to monitor compliance with cancer drug margin caps - Business Standard
Centre directs states to monitor compliance with cancer drug margin caps Business Standard
Google News
Nov 13, 2026, 12:40 PM
Deputy PM highlighted industry, agriculture, and pharmaceuticals as promising sectors for Belarus-Vietnam co-operation - СБ. Беларусь сегодня
Deputy PM highlighted industry, agriculture, and pharmaceuticals as promising sectors for Belarus-Vietnam co-operation СБ. Беларусь сегодня
Google News
Nov 13, 2026, 12:09 PM
Kwality Pharma Q2 FY27 slides: guidance raised on margin expansion - Investing.com
Kwality Pharma Q2 FY27 slides: guidance raised on margin expansion Investing.com
Google News
Nov 13, 2026, 12:09 PM
NATCO Pharma Q2 FY27 slides: sequential rebound lifts profit outlook - Investing.com
NATCO Pharma Q2 FY27 slides: sequential rebound lifts profit outlook Investing.com
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer